Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City - Soligenix

Presentation to be Webcast Live, 11:40 AM EDT, September 9th

Princeton, NJ – September 5, 2013 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City, Monday, September 9, at 11:40 AM Eastern Daylight Time. The presentation will take place in room 7.03 at the Millennium Broadway Hotel.

The Soligenix presentation will be webcast live and archived for later replay. To access the webcast, please visit the company’s investor page.  A replay of the presentation will be archived after the conference at the same location.

For more information about the Rodman & Renshaw Global Investment Conference, please refer to the conference Website at http://www.meetmax.com/sched/event_20174/~public/conference_home.html?event_id=20174.

About Soligenix, Inc.

Soligenix is a clinical stage biopharmaceutical company developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. Soligenix is developing proprietary formulations of oral BDP (beclomethasone 17,21-dipropionate) for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn’s disease (SGX203), acute radiation enteritis (SGX201) and chronic Graft-versus-Host disease (orBec®), as well as developing its novel innate defense regulator (IDR) technology SGX942 for the treatment of oral mucositis.

Through its BioDefense Division, Soligenix is developing countermeasures pursuant to the Biomedical Advanced Research and Development Authority (BARDA) Strategic Plan of 2011-2016 for inclusion in the US government’s Strategic National Stockpile. Soligenix’s lead biodefense products in development are a recombinant subunit vaccine called RiVax™, which is designed to protect against the lethal effects of exposure to ricin toxin and VeloThrax™, a vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Both RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National Institute of Allergy and Infectious Diseases (NIAID) grant supporting development of Soligenix’s new vaccine heat stabilization technology known as ThermoVax™. Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under a $600,000 NIAID Small Business Innovation Research (SBIR) grant. OrbeShield™ has previously demonstrated statistically significant preclinical survival results in two separate canine GI ARS studies funded by the NIAID.  Recently, Soligenix announced a worldwide exclusive collaboration with Intrexon Corporation that will focus on the joint development of a treatment for Melioidosis, a high priority biothreat and an area of unmet medical need.

For further information regarding Soligenix, Inc., please visit the Company’s Website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.’s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment.  Statements that are not historical facts, such as “anticipates,” “estimates,” “believes,” “intends,” “potential,” or similar expressions, are forward-looking statements.  These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements.  Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats conducting preclinical and clinical trials of vaccines, obtaining regulatory approvals and manufacturing vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program.  These and other risk factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, Soligenix’s reports on Forms 10-Q and 10-K.  Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Soligenix to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
Go Back
Try to ensure there will be no hidden costs that might sometimes be imposed by certain companies, such as the fees for some additional services or some other extra expenses. This will allow you to be fully confident that you will not have to pay any extra cash. The above-mentioned points indicate that there are many risks associated with purchasing drugs from online companies, although it still remains a highly convenient way to get what you need timely and without unwanted trouble. Additional Facts about Buying Drugs from canadianrxantibiotics.com Online Above all, you should ensure that you are guaranteed timely delivery, especially if you need your drugs to be delivered to you as soon as possible. Sometimes, there might be certain restrictions imposed by the border protection services, which might result in the untimely delivery of your drugs. Nevertheless, it is always better to take the necessary precautions in advance by contacting the company whose services you are using and letting them know that you need to get your medications without delays. This is especially vital if you have never used the services of the chosen drugstore before and do not know much about their reliability.